|
1 Introduction to Basic Immunology and Techniques |
|
|
1 | (18) |
|
|
|
1 | (3) |
|
1.1 Basic immunology and techniques |
|
|
4 | (2) |
|
|
6 | (2) |
|
|
8 | (1) |
|
1.4 Antigen-antibody reactions |
|
|
9 | (1) |
|
1.5 Antibody-mediated red cell destruction |
|
|
10 | (3) |
|
1.6 In vitro detection of antigen-antibody reactions |
|
|
13 | (4) |
|
|
17 | (2) |
|
|
18 | (1) |
|
2 Human Blood Group Antigens |
|
|
19 | (43) |
|
|
|
19 | (1) |
|
2.1 Human polymorphism and evolution |
|
|
20 | (3) |
|
2.2 The erythrocyte membrane |
|
|
23 | (4) |
|
2.3 Blood group systems dependent on carbohydrate structures |
|
|
27 | (6) |
|
2.4 Blood group systems dependent on protein structures |
|
|
33 | (24) |
|
2.5 Non-polymorphic erythrocyte membrane proteins |
|
|
57 | (1) |
|
2.6 Blood group genotyping(BGG) |
|
|
58 | (4) |
|
|
60 | (1) |
|
|
61 | (1) |
|
3 Haemolytic Disease of the Fetus and Newborn |
|
|
62 | (20) |
|
|
|
62 | (1) |
|
3.1 Fetal alloimmunization |
|
|
63 | (6) |
|
3.2 Clinical management-laboratory investigations |
|
|
69 | (3) |
|
|
72 | (4) |
|
3.4 Neonatal alloimmune thrombocytopaenia (NAITP) |
|
|
76 | (1) |
|
|
76 | (1) |
|
3.6 Clinical management--obstetrics |
|
|
77 | (3) |
|
|
80 | (2) |
|
|
80 | (1) |
|
|
80 | (2) |
|
4 Clinical Use of Blood Components |
|
|
82 | (26) |
|
|
|
82 | (1) |
|
4.1 Structure and function of blood |
|
|
83 | (1) |
|
4.2 Normal physiological response to anaemia and/or bleeding |
|
|
83 | (1) |
|
|
84 | (2) |
|
4.4 Blood components available and their appropriate use |
|
|
86 | (6) |
|
|
92 | (1) |
|
|
93 | (1) |
|
|
93 | (5) |
|
4.8 Decision making, who needs a transfusion, risks and benefits |
|
|
98 | (2) |
|
4.9 Alternatives to donor blood |
|
|
100 | (5) |
|
4.10 Case history examples |
|
|
105 | (3) |
|
|
106 | (1) |
|
|
107 | (1) |
|
5 Microbiological Testing of Blood Donations |
|
|
108 | (33) |
|
|
|
|
|
108 | (1) |
|
5.1 Requirements for microbiological testing of blood donations |
|
|
109 | (1) |
|
5.2 The virus life cycle: basic biology |
|
|
110 | (1) |
|
5.3 Epidemiology for hepatitis B and C and for HIV (AIDS) |
|
|
111 | (8) |
|
5.4 Screening strategy for mandatory viral tests |
|
|
119 | (6) |
|
5.5 Testing strategy to protect immunocompromised patients |
|
|
125 | (1) |
|
5.6 Bacterial tests for products stored at room temperature |
|
|
126 | (3) |
|
5.7 Emerging issues for blood safety |
|
|
129 | (1) |
|
5.8 Insect/animal-borne pathogens |
|
|
130 | (2) |
|
5.9 Arthropod (insect)-borne viruses, i.e. ARBO viruses |
|
|
132 | (2) |
|
5.10 Transmissible spongiform encephalitis, prions, and variant Creutzfeldt-Jakob disease |
|
|
134 | (2) |
|
5.11 Quality control and blood safety |
|
|
136 | (2) |
|
5.12 Strategies for the future and conclusion |
|
|
138 | (3) |
|
|
138 | (1) |
|
|
139 | (2) |
|
6 Human Platelet Antigens (HPA) and Human Neutrophil Antigens (HNA) and Their Clinical Significance |
|
|
141 | (40) |
|
|
|
142 | (1) |
|
6.1 Overview of platelet and granulocyte antigens |
|
|
142 | (2) |
|
6.2 Human platelet antigens (HPA) |
|
|
144 | (7) |
|
6.3 Human neutrophil antigens (HNA) |
|
|
151 | (4) |
|
|
155 | (10) |
|
6.5 Clinical significance of HPA alloantibodies |
|
|
165 | (9) |
|
6.6 Clinical significance of HNA antibodies |
|
|
174 | (7) |
|
|
178 | (1) |
|
|
179 | (1) |
|
|
180 | (1) |
|
7 Compatibility Testing and Adverse Effects |
|
|
181 | (28) |
|
|
|
181 | (1) |
|
7.1 Compatibility testing (serological and non-serological) |
|
|
182 | (10) |
|
7.2 Selection of plasma products |
|
|
192 | (1) |
|
7.3 Selection of cellular components |
|
|
193 | (1) |
|
7.4 Visual inspection and labelling of the units |
|
|
194 | (1) |
|
7.5 Traceability of blood components |
|
|
195 | (1) |
|
7.6 Adverse effects of transfusion |
|
|
195 | (4) |
|
7.7 Monitoring the patient during transfusion |
|
|
199 | (1) |
|
7.8 Investigation of transfusion reactions |
|
|
200 | (3) |
|
7.9 Haemovigilance in the UK |
|
|
203 | (6) |
|
|
207 | (1) |
|
|
207 | (2) |
|
8 Immune-Mediated Red Cell Destruction |
|
|
209 | (20) |
|
|
|
209 | (1) |
|
8.1 What is immune (antibody-mediated) red cell destruction? |
|
|
210 | (2) |
|
8.2 Clinical significance of red cell antibodies |
|
|
212 | (3) |
|
8.3 Haemolytic transfusion reactions |
|
|
215 | (3) |
|
8.4 Autoimmune haemolytic anaemias (AIHA) |
|
|
218 | (7) |
|
8.5 Haemolysis post-transplantation of bone marrow/stem cell transplant |
|
|
225 | (1) |
|
8.6 Haemolysis post-solid organ transplant and hyperacute rejection |
|
|
226 | (1) |
|
8.7 Haemolytic disease of the fetus and newborn (HDFN) |
|
|
227 | (2) |
|
|
227 | (1) |
|
|
227 | (2) |
|
9 Human Leucocyte Antigens (HLA) and Their Clinical Significance |
|
|
229 | (30) |
|
|
|
229 | (1) |
|
9.1 A brief history of transplantation |
|
|
230 | (1) |
|
9.2 Human leucocyte antigens |
|
|
231 | (6) |
|
9.3 The detection and definition of human leucocyte antigens, alleles, and antibodies |
|
|
237 | (5) |
|
9.4 Clinical significance of human leucocyte antigens in transplantation |
|
|
242 | (7) |
|
9.5 Clinical significance of human leucocyte antigens in transfusion |
|
|
249 | (4) |
|
|
253 | (2) |
|
|
255 | (4) |
|
|
257 | (1) |
|
|
258 | (1) |
|
|
258 | (1) |
|
10 Haematopoietic Stem Cell Transplantation and Stem Cell Plasticity |
|
|
259 | (28) |
|
|
|
|
259 | (1) |
|
|
260 | (2) |
|
10.2 The bone marrow microenvironment |
|
|
262 | (1) |
|
10.3 Sources and collection of haematopoietic SCs |
|
|
263 | (9) |
|
10.4 Stem cell transplantation |
|
|
272 | (6) |
|
10.5 Novel approaches to personalized medicine and stem cell plasticity |
|
|
278 | (7) |
|
|
285 | (2) |
|
|
285 | (1) |
|
|
286 | (1) |
|
|
287 | (28) |
|
|
|
|
|
287 | (1) |
|
|
288 | (1) |
|
11.2 Which tissues are banked and how are they used? |
|
|
289 | (2) |
|
11.3 How are donors selected, screened, and consented? |
|
|
291 | (3) |
|
11.4 How are tissues retrieved? |
|
|
294 | (4) |
|
11.5 Tissue processing and preservation |
|
|
298 | (7) |
|
11.6 Storage and distribution |
|
|
305 | (5) |
|
11.7 The future-regenerative medicine |
|
|
310 | (5) |
|
|
312 | (1) |
|
|
313 | (2) |
|
|
315 | (14) |
|
|
|
315 | (1) |
|
12.1 Evolution of quality |
|
|
316 | (2) |
|
12.2 Quality management systems |
|
|
318 | (4) |
|
12.3 Blood safety and quality regulations |
|
|
322 | (2) |
|
12.4 The In Vitro Diagnostic Medical Devices Directive |
|
|
324 | (1) |
|
12.5 Clinical laboratory accreditation |
|
|
324 | (1) |
|
12.6 The Blood Stocks Management Scheme |
|
|
325 | (1) |
|
12.7 Other legislation and regulatory bodies |
|
|
326 | (1) |
|
|
327 | (1) |
|
|
327 | (2) |
|
|
328 | (1) |
|
|
328 | (1) |
Glossary |
|
329 | (6) |
Abbreviations |
|
335 | (4) |
Index |
|
339 | |